Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 39 of 41
Comparison of Early and Late Therapy for Adults With Non-Operatively Treated Proximal Humerus Fractures
NCT00438633
Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1
NCT00218634
Risk of Attention Deficit Hyperactivity Disorder (ADHD) in the Children of Adults With ADHD Not Otherwise Specified (NOS)
NCT00181857
EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial
NCT00233038
Effect of Race on Gonadotropin Responses
NCT00455962
Recombinant Human Prolactin for Lactation Induction
NCT00181623
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
NCT00142428
Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder
NCT00181844
Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder
NCT00181896
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
NCT00142480
A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults
NCT00302354
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
NCT00113828
Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
NCT00131378
Anastrozole Administration in Elderly Hypogonadal Men
NCT00136695
Proton Radiation Therapy (RT) for the Treatment of Pediatric Rhabdomyosarcoma
NCT00592592
Androgen Effects in HIV-infected Women
NCT00095212
Dose-Response of Gonadal Steroids and Bone Turnover in Older Men
NCT00114114
Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer
NCT00087347
Effect of Propranolol on Preventing Posttraumatic Stress Disorder
NCT00158262
Recombinant Human Prolactin for Lactation Induction
NCT00181610
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
NCT00181805
Study of Paxil Use in Menopausal Women
NCT00225914
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
NCT01048840
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
NCT00218322
Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
NCT00181948
Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder
NCT00118911
Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency
NCT00182091
Testing the Right Question Project (RQP) Health Education Strategy in a Mental Health Setting
NCT00134615
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
NCT00455702
Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.
NCT00299780
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
NCT00566735
Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
NCT00135720
Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome
NCT00114127
Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
NCT00086619
Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer
NCT00084669
Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression
NCT00093847
Inflammation and the Host Response to Injury (Burns)
NCT00257244
The Effects of Nicotine on Cognition in Schizophrenia
NCT00383747
Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder
NCT00106223
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
NCT00142467
Study of TNF-Antagonism in Metabolic Syndrome
NCT00409318
A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
NCT00135733
Fetal Alcohol Damage Prevention Study
NCT00696085
Antibiotic Efficacy in Third Molar Surgery
NCT00118820
Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder
NCT00113295
Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate
NCT00585962
Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
NCT00585910
Physiologic Growth Hormone Effects in HIV Lipodystrophy
NCT00100698
Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder
NCT00181727
An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects
NCT00302367
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.